Study To Assess The Safety And Tolerability Of Increasing Single Doses Of ATR-107 (PF-05230900) In Healthy People

Summary

This is a "first in human" study to determine the safety and tolerability of the drug after single doses. Nine doses of increasing strength will be injected or infused (given into a vein) to 9 different groups of people. One third of the participants will be given an injection or infusion of placebo (sugar water). All participants will be healthy people.

Conditions

• Healthy

Interventions

DRUG

Placebo SC Injection

Single injection

DRUG

ATR-107 (PF-05230900) SC Injection

Single intravenous infusion, 60 minute duration

DRUG

ATR-107 (PF-05230900) SC Injection

Single subcutaneous injection

DRUG

ATR-107 (PF-05230900) SC Injection

Single subcutaneous injection

DRUG

ATR-107 (PF-05230900) SC Injection

Single subcutaneous injection

DRUG

ATR-107 (PF-05230900) SC Injection

Single subcutaneous injection

DRUG

ATR-107 (PF-05230900) IV Infusion

Single subcutaneous injection

DRUG

ATR-107 (PF-05230900) IV Infusion

Single intravenous infusion, 60 minute duration

DRUG

ATR-107 (PF-05230900) IV Infusion

Single intravenous infusion, 60 minute duration

DRUG

Placebo IV Infusion

Single intravenous infusion, 60 minute duration

DRUG

ATR-107 (PF-05230900) IV Infusion

Single intravenous infusion, 60 minute duration

Sponsors & Collaborators

• Pfizer

  lead INDUSTRY

Principal Investigators

• Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation

RANDOMIZED

Masking

DOUBLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

55 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2010-06-30

Primary Completion

2012-01-31

Completion

2012-01-31

Countries

• United States

Study Locations